Elona Accomplishments

Elona Biotechnologies, Inc. Accomplishments

(Greenwood, Ind. – March 4, 2010) – R&D Enterprises, LLC, a subsidiary of Elona Biotechnologies, Inc., announced today that it has filed an IND with the FDA for a biogeneric form of insulin which, if approved, is expected to significantly reduce the cost of insulin for diabetic patients in the U.S. and eventually around the world.
“We have developed a unique, proprietary and iterative system that utilizes improved cell banking and protein expression technology which has significantly enhanced purification yields,” said Ron Zimmerman Sr., President of Elona. “If approved, this product will offer a high quality, low cost option to patients who otherwise cannot afford insulin,” he said.